Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celldex Therapeutics, Inc.    

CELLDEX THERAPEUTICS, INC.

  Report  
 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2019 5,10 M
EBIT 2019 -61,1 M
Net income 2019 -60,3 M
Debt 2019 -
Yield 2019 -
Sales 2020 6,00 M
EBIT 2020 -66,6 M
Net income 2020 -66,3 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 9,24x
Capi. / Sales2020 7,86x
Capitalization 47,1 M
More Financials
Company
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic... 
More about the company
Latest news on CELLDEX THERAPEUTICS, INC.
04/03CELLDEX THERAPEUTICS : Presents Positive Interim Results from Phase 1 Study of C..
AQ
04/02CELLDEX THERAPEUTICS : Presents Promising Data from CDX-527 Bispecific and TAM R..
AQ
04/02CELLDEX THERAPEUTICS : Presents Positive Interim Results from Phase 1 Study of C..
AQ
04/01Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Prog..
GL
03/08CELLDEX THERAPEUTICS : Provides Corporate Update and Reports Full Year 2018 Resu..
AQ
03/07CELLDEX THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
03/07CELLDEX THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fina..
AQ
03/07CELLDEX THERAPEUTICS : Provides Corporate Update and Reports Full Year 2018 Resu..
AQ
03/04CELLDEX THERAPEUTICS : to Report Full Year 2018 Business/Financial Results and H..
AQ
03/01Celldex to Report Full Year 2018 Business/Financial Results and Host Corporat..
GL
More news
Analyst Recommendations on CELLDEX THERAPEUTICS, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CELLDEX THERAPEUTICS, INC.
Duration : Period :
Celldex Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 19,0 $
Spread / Average Target 401%
EPS Revisions
Managers
NameTitle
Anthony S. Marucci President, Chief Executive Officer & Director
Larry Ellberger Chairman
Sam Martin Chief Financial Officer, Secretary & Senior VP
Tibor Keler Chief Scientific Officer & Executive VP
Karen Lipton Shoos Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLDEX THERAPEUTICS, INC.2,694.34%47
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%22 914
LONZA GROUP16.76%21 810
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596